These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 29540182)
1. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. Heby M; Lundgren S; Nodin B; Elebro J; Eberhard J; Jirström K J Transl Med; 2018 Mar; 16(1):66. PubMed ID: 29540182 [TBL] [Abstract][Full Text] [Related]
2. The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. Lundgren S; Karnevi E; Elebro J; Nodin B; Karlsson MCI; Eberhard J; Leandersson K; Jirström K J Transl Med; 2017 Jul; 15(1):152. PubMed ID: 28673320 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. Elebro J; Heby M; Gaber A; Nodin B; Jonsson L; Fristedt R; Uhlén M; Jirström K; Eberhard J J Transl Med; 2014 Oct; 12():289. PubMed ID: 25323550 [TBL] [Abstract][Full Text] [Related]
4. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587 [TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. González I; Goyal B; Xia MD; Pai RK; Ma C Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262 [TBL] [Abstract][Full Text] [Related]
6. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy. Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397 [TBL] [Abstract][Full Text] [Related]
7. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. Heby M; Elebro J; Nodin B; Jirström K; Eberhard J BMC Clin Pathol; 2015; 15():10. PubMed ID: 26028992 [TBL] [Abstract][Full Text] [Related]
9. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. Elebro J; Heby M; Warfvinge CF; Nodin B; Eberhard J; Jirström K PLoS One; 2016; 11(4):e0153533. PubMed ID: 27070783 [TBL] [Abstract][Full Text] [Related]
10. Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. Lundgren S; Elebro J; Heby M; Nodin B; Leandersson K; Micke P; Jirström K; Mezheyeuski A Int J Cancer; 2020 Jun; 146(12):3461-3473. PubMed ID: 32129882 [TBL] [Abstract][Full Text] [Related]
11. The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. Lundgren S; Warfvinge CF; Elebro J; Heby M; Nodin B; Krzyzanowska A; Bjartell A; Leandersson K; Eberhard J; Jirström K PLoS One; 2016; 11(6):e0156497. PubMed ID: 27275582 [TBL] [Abstract][Full Text] [Related]
12. Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival. Williams JL; Chan CK; Toste PA; Elliott IA; Vasquez CR; Sunjaya DB; Swanson EA; Koo J; Hines OJ; Reber HA; Dawson DW; Donahue TR JAMA Surg; 2017 Jan; 152(1):82-88. PubMed ID: 27732711 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776 [TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors. El Nakeeb A; El Sorogy M; Ezzat H; Said R; El Dosoky M; Abd El Gawad M; Elsabagh AM; El Hanafy E Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):443-449. PubMed ID: 30126828 [TBL] [Abstract][Full Text] [Related]
15. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study. Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872 [TBL] [Abstract][Full Text] [Related]
16. Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome. Lundgren S; Hau SO; Elebro J; Heby M; Karnevi E; Nodin B; Eberhard J; Holm K; Staaf J; Jönsson GB; Jirström K JCO Precis Oncol; 2019; 3():. PubMed ID: 32914025 [TBL] [Abstract][Full Text] [Related]
17. Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. Fristedt R; Elebro J; Gaber A; Jonsson L; Heby M; Yudina Y; Nodin B; Uhlén M; Eberhard J; Jirström K PLoS One; 2014; 9(11):e112728. PubMed ID: 25397670 [TBL] [Abstract][Full Text] [Related]
18. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer. Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018 [TBL] [Abstract][Full Text] [Related]
19. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. Otsuka H; Murakami Y; Uemura K; Kondo N; Nakagawa N; Okada K; Seo S; Takahashi S J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):421-428. PubMed ID: 32219999 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer]. Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]